# ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

> **NCT05532722** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abcuro, Inc.** · enrollment: 21 (actual)

## Conditions studied

- T-cell Large Granular Lymphocytic Leukemia

## Interventions

- **DRUG:** ABC008

## Key facts

- **NCT ID:** NCT05532722
- **Lead sponsor:** Abcuro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-28
- **Primary completion:** 2025-08-28
- **Final completion:** 2026-03-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532722, "ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05532722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*